8-K: Ocuphire Pharma Advances Diabetic Retinopathy Program with Positive Phase 2 Data and Strategic Partnership

Ocuphire Pharma is progressing its diabetic retinopathy program with a focus on oral treatment APX3330, supported by positive Phase 2 results and a partnership with Viatris for Ryzumvi.

Summary

• Ocuphire Pharma is developing APX3330, an oral treatment for diabetic retinopathy (DR), targeting multiple disease pathways.
• The company completed an end-of-Phase 2 meeting with the FDA, achieving alignment on a primary endpoint for a pivotal Phase 2/3 study.
• Phase 2 results for APX3330 showed fewer treated subjects experienced DR worsening compared to placebo, using a 3-step DRSS worsening on a binocular scale.
• Fewer APX3330-treated subjects developed proliferative diabetic retinopathy (PDR), an advanced form of the disease, compared to placebo.
• The company has a partnership with Viatris for Ryzumvi, which is expected to launch in the first half of 2024 for the reversal of pharmacologically-induced mydriasis.
• The Ryzumvi partnership includes two ongoing, funded Phase 3 studies in decreased visual acuity under low light conditions and presbyopia, with potential for double-digit royalties and milestone payments.
• The diabetic retinopathy market is large and underserved, with an estimated $6 billion market for non-proliferative diabetic retinopathy (NPDR).
• The company is planning a Phase 2/3 study (ZETA-2) with an enriched patient population of high-risk NPDR progressors.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising Phase 2 data, a strategic partnership, and a large market opportunity. The company is well-positioned to advance its diabetic retinopathy program, although some risks remain.

Positives

• APX3330 is an oral treatment, which is less invasive than current standard of care treatments.
• The company has achieved FDA alignment on the primary endpoint for the pivotal Phase 2/3 study.
• Phase 2 results showed a reduction in DR worsening and PDR development with APX3330.
• The partnership with Viatris provides significant funding and commercialization support for Ryzumvi.
• The company has a strong management team with extensive experience in ophthalmology.
• The company has a revenue-generating partnership with Viatris, strengthening its cash position.

Negatives

• The Phase 2 study did not show statistically significant differences between the APX3330 and placebo groups.
• The company is still in the clinical trial phase and has not yet received regulatory approval for APX3330.
• The company is reliant on third parties for manufacturing and commercialization.
• The company faces competition from other companies developing treatments for diabetic retinopathy.

Risks

• The success and timing of regulatory submissions and clinical trials are uncertain.
• There are risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates.
• The company faces substantial competition and rapid technological change in the pharmaceutical industry.
• The partnership with Viatris may not facilitate the commercialization or market acceptance of Ocuphire's product candidates.
• There are risks related to future fluctuations in the market price of the company's common stock.

Future Outlook

Ocuphire plans to launch Ryzumvi in the first half of 2024 and initiate a pivotal Phase 2/3 study (ZETA-2) for APX3330 in diabetic retinopathy. The company also intends to continue the development of its other pipeline candidates.

Management Comments

• Jeff Heier, MD, stated that if ZETA-1 results are repeated in Phase 3, he would place virtually all of his diabetic patients on oral APX3330 and treat locally only as needed.
• Peter Kaiser, MD, noted that Ref-1 biology targets three pillars of diabetic eye disease: angiogenesis, inflammation, and oxidative stress.
• Arshad Khanani, MD, expressed his enjoyment in working with the team to develop an innovative protocol design to enroll the patients most likely to have progressive disease while keeping the study practical to help enrollment.

Industry Context

The announcement highlights Ocuphire's efforts to address the large and underserved diabetic retinopathy market, where current treatments are often invasive and target only single disease pathways. The development of an oral treatment like APX3330 could represent a significant advancement in the field. The partnership with Viatris is also a strategic move to leverage a global commercialization partner.

Comparison to Industry Standards

• Current standard of care for diabetic retinopathy includes invasive treatments such as intravitreal injections of anti-VEGF therapies like Eylea and Lucentis, which target only angiogenesis.
• Ocuphire's APX3330 is an oral treatment that targets multiple pathways, including angiogenesis, oxidative stress, and inflammation, which is a novel approach compared to existing therapies.
• Other companies are also developing oral treatments for diabetic retinopathy, such as Runcaciguat, OPL-0401, and VX-1, but APX3330 is the most advanced oral candidate in development.
• The company's partnership with Viatris for Ryzumvi is similar to other licensing agreements in the pharmaceutical industry, where smaller companies partner with larger companies for commercialization.

Stakeholder Impact

• Shareholders may benefit from the potential for future revenue and growth.
• Employees may benefit from the company's growth and success.
• Patients with diabetic retinopathy may benefit from the development of new and effective treatments.
• Viatris will benefit from the commercialization of Ryzumvi.

Next Steps

• Launch Ryzumvi in the first half of 2024.
• Initiate the pivotal Phase 2/3 study (ZETA-2) for APX3330 in diabetic retinopathy.
• Continue the development of other pipeline candidates.

Key Dates

Keywords

Diabetic Retinopathy, APX3330, RYZUMVI, Ophthalmology, NPDR, PDR, Viatris, Clinical Trial, FDA, Ref-1 Inhibitor